The significant improvement in the activity of PON-1 sheds a light to the promising therapeutic effectiveness of metformin + lycopene for the management of metabolic complications resulting from oxidative stress, especially cardiovascular diseases. The gene discussed is PON1; the disease is cardiovascular disorder.